Shares of Celyad SA (NASDAQ:CYAD) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price objective of $74.00 for the company, according to Zacks. Zacks has also given Celyad an industry rank of 161 out of 265 based on the ratings given to its competitors.

Several equities analysts have weighed in on CYAD shares. ValuEngine lowered Celyad from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Piper Jaffray Companies restated an “overweight” rating and set a $74.00 target price on shares of Celyad in a research report on Monday, October 9th.

Shares of Celyad (NASDAQ CYAD) traded up $1.19 during midday trading on Friday, reaching $45.44. The company’s stock had a trading volume of 879 shares, compared to its average volume of 4,642. Celyad has a 1-year low of $19.57 and a 1-year high of $64.75.

ILLEGAL ACTIVITY NOTICE: “” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at

About Celyad

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Get a free copy of the Zacks research report on Celyad (CYAD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply